cilostazol has been researched along with adenosine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M | 1 |
| Cone, J; Fong, M; Liu, Y; Wang, S; Yoshitake, M | 1 |
| Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M | 1 |
| Fong, M; Guertin, M; Kambayashi, J; Le, SN; Lin, S; Liu, Y; Sun, B; Tandon, NN; Yoshitake, M | 1 |
| Huang, MH; Liu, SI; Wu, SN | 1 |
| Bricmont, P; Cone, J; Czerwiec, FS; Fong, M; Kambayashi, J; Le, SN; Liu, Y; Shoaf, SE; Sun, B; Tao, L; Yoshitake, M | 1 |
| Iwata, M; Nakamura, T; Uchiyama, S; Yamazaki, M | 1 |
| Birnbaum, Y; Huang, MH; Hughes, MG; Lin, Y; Lui, CY; Manickavasagam, S; McAdoo, DJ; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
| Grove, EL; Kristensen, SD | 1 |
| Fong, M; Kambayashi, J; Liu, Y; Yoshitake, M | 1 |
| Easton, JD | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y | 1 |
| Reis, F | 1 |
| Fan, L; Liu, J; Yang, L; Zhang, C; Zhou, J | 1 |
| Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E | 1 |
| Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y | 1 |
| Angiolillo, D; Birnbaum, Y; Khawaja, M; Kherallah, RY; Olson, M | 1 |
7 review(s) available for cilostazol and adenosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Occlusive Diseases; Cell Division; Cilostazol; Coronary Restenosis; Coronary Thrombosis; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Fibrinolytic Agents; Humans; Hypolipidemic Agents; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Vasodilator Agents | 2001 |
Update on oral antiplatelet therapy: principles, problems and promises.
Topics: Adenosine; Administration, Oral; Cardiovascular Diseases; Cilostazol; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Tetrazoles; Thiophenes; Thromboxane A2; Ticagrelor | 2009 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Topics: Adenosine; Cilostazol; Humans; Intermittent Claudication; Platelet Aggregation Inhibitors; Stroke; Tetrazoles | 2022 |
1 trial(s) available for cilostazol and adenosine
| Article | Year |
|---|---|
Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
Topics: Adenosine; Animals; Blood Platelets; CHO Cells; Cilostazol; Cricetinae; Cyclic AMP; Dipyridamole; Drug Synergism; Humans; Intracellular Membranes; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Time Factors | 2004 |
12 other study(ies) available for cilostazol and adenosine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Topics: Adenosine; Animals; Blood Pressure; Cilostazol; Dose-Response Relationship, Drug; Heart Rate; Humans; Intermittent Claudication; Male; Milrinone; Myocardial Ischemia; Pentoxifylline; Phosphodiesterase Inhibitors; Rabbits; Tetrazoles; Thioinosine | 2000 |
Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Animals; Cilostazol; Contraindications; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart; Hemodynamics; In Vitro Techniques; Male; Milrinone; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Rabbits; Tetrazoles; Vasodilator Agents | 2001 |
New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation.
Topics: Adenosine; Analysis of Variance; Animals; CHO Cells; Cilostazol; Cricetinae; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Platelet Activation; Tetrazoles | 2002 |
Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Action Potentials; Adenoma; Adenosine; Adenosine Diphosphate; Animals; Calcium Channels, L-Type; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Electric Conductivity; Enzyme Inhibitors; Kinetics; Large-Conductance Calcium-Activated Potassium Channels; PC12 Cells; Phosphodiesterase Inhibitors; Pituitary Gland, Anterior; Pituitary Neoplasms; Potassium Channels, Calcium-Activated; Rats; Tetrazoles | 2004 |
Synergistic effect of cilostazol and dipyridamole mediated by adenosine on shear-induced platelet aggregation.
Topics: Adenosine; Adult; Cilostazol; Dipyridamole; Drug Synergism; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Shear Strength; Tetrazoles | 2007 |
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
Topics: Adenosine; Administration, Oral; Animals; Atorvastatin; Body Weight; Cilostazol; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Immunoblotting; Male; Myocardium; Nitric Oxide Synthase Type III; Organ Culture Techniques; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Risk Factors; Tetrazoles; Treatment Outcome | 2007 |
Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle.
Topics: Adenosine; AMP Deaminase; Animals; Cilostazol; Dose-Response Relationship, Drug; Electric Stimulation; Male; Milrinone; Models, Animal; Muscle Contraction; Muscle, Skeletal; Phosphodiesterase 3 Inhibitors; Piperazines; Rabbits; Regional Blood Flow; Tetrazoles; Vasodilator Agents | 2010 |
Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels.
Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Decanoic Acids; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Hydroxy Acids; Myocardial Infarction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Potassium Channel Blockers; Purinergic P1 Receptor Antagonists; Rabbits; Reperfusion Injury; Superoxides; Tetrazoles; Theophylline | 2011 |
Are threshold levels of signal transduction required for the protective effect of cilostazol against cardiac ischaemia-reperfusion injury?
Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Humans; Myocardial Infarction; Nitric Oxide; Potassium Channel Blockers; Reperfusion Injury; Tetrazoles | 2011 |
Loading solution prevents activation damage of human platelets before lyophilization.
Topics: Adenosine; Algorithms; Alprostadil; Arginine; Biomarkers; Blood Platelets; Blood Preservation; Cell Size; Cilostazol; Excipients; Freeze Drying; Hirudins; Humans; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Membrane Glycoproteins; Recombinant Proteins; Tetrazoles | 2011 |
Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; China; Cilostazol; Clopidogrel; Cyclic AMP; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Function Tests | 2021 |